Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$61.74

-0.61 (-0.98%)

10:55
10/07/16
10/07
10:55
10/07/16
10:55

Sarepta put volume heavy and directionally bearish

Bearish flow noted in Sarepta with 7,596 puts trading, or 1.0x expected. Most active are Jan-17 65 calls and 10/7 weekly 59 puts, with total volume in those strikes near 2,700 contracts. The Put/Call Ratio is 1.62, while ATM IV is up over 2 points on the day. Earnings are expected on November 3rd.

  • 06

    Nov

SRPT Sarepta
$61.74

-0.61 (-0.98%)

10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $68
PIPR
Overweight
Piper Jaffray ups Sarepta target to $68 on Summit deal
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics (SRPT) to $68 from $64 after the company licensed Summit Therapeutics' (SMMT) ezutromid to treat Duchenne Muscular Dystrophy in Europe, Turkey and the Commonwealth of Independent States. The deal is a smart way for Sarepta to capitalize on its lead in DMD with the recent FDA approval of Exondys51, Tenthoff tells investors in an intraday research note. His new price target of $68 reflects the value of ezutromid. Tenthoff reiterates an Overweight rating on Sarepta. The stock is up 1% to $61.61 in late morning trading. Summit is up 94%, or $8.17, to $16.82.
09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
09/28/16
09/28/16
NO CHANGE

Experts 'fairly upbeat' on Sarepta drug, says RBC Capital
After speaking with three neurologists who treat DMD, RBC Capital analyst Simos Simeonidis says that the doctors were "fairly bullish" on Sarepta's DMD treatment, EXONDYS 51. The doctors expect to use the drug "in essentially all eligible patients," according to the analyst. Simeonidis raised the price target on Sarepta to $108 from $83 and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

CPN

Calpine

$9.59

-0.33 (-3.33%)

06:05
04/28/17
04/28
06:05
04/28/17
06:05
Earnings
Calpine reports Q1 EPS (16c), consensus (12c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBR

KBR

$15.48

-0.02 (-0.13%)

06:04
04/28/17
04/28
06:04
04/28/17
06:04
Earnings
KBR reports Q1 EPS ex-items 28c, consensus 29c »

Reports Q1 revenue $1.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

DRAD

Digirad Corp

$5.15

-0.05 (-0.96%)

06:04
04/28/17
04/28
06:04
04/28/17
06:04
Earnings
Digirad Corp reports Q1 adjusted EPS (1c), consensus 5c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 28

    Apr

HST

Host Hotels

$19.24

-0.03 (-0.16%)

06:03
04/28/17
04/28
06:03
04/28/17
06:03
Earnings
Host Hotels sees FY17 EPS 73c-81c, consensus 67c »

Sees FY17 GAAP revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

GIMO

Gigamon

$36.00

-0.6 (-1.64%)

06:03
04/28/17
04/28
06:03
04/28/17
06:03
Downgrade
Gigamon rating change  »

Gigamon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

AVT

Avnet

$40.86

-3.72 (-8.34%)

06:02
04/28/17
04/28
06:02
04/28/17
06:02
Downgrade
Avnet rating change  »

Avnet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$68.27

0.44 (0.65%)

06:02
04/28/17
04/28
06:02
04/28/17
06:02
Recommendations
Microsoft analyst commentary  »

Piper an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 09

    May

ZEUS

Olympic Steel

$19.23

-0.64 (-3.22%)

06:02
04/28/17
04/28
06:02
04/28/17
06:02
Earnings
Olympic Steel reports Q1 EPS 68c, consensus 40c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 28

    Apr

HST

Host Hotels

$19.24

-0.03 (-0.16%)

06:01
04/28/17
04/28
06:01
04/28/17
06:01
Earnings
Host Hotels reports Q1 EPS 21c, consensus 15c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

CVNA

Carvana

06:01
04/28/17
04/28
06:01
04/28/17
06:01
Syndicate
Carvana 15M share IPO priced at $15.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

ZYME

Zymeworks

06:00
04/28/17
04/28
06:00
04/28/17
06:00
Syndicate
Zymeworks 4.5M share IPO priced at $13.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

POR

Portland General Electric

$46.38

0.13 (0.28%)

06:00
04/28/17
04/28
06:00
04/28/17
06:00
Earnings
Breaking Earnings news story on Portland General Electric »

Portland General Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

FB

Facebook

$147.70

1.14 (0.78%)

06:00
04/28/17
04/28
06:00
04/28/17
06:00
Hot Stocks
Facebook makes Messenger Lite available in 150 additional countries »

Facebook's head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 08

    May

  • 16

    May

POR

Portland General Electric

$46.38

0.13 (0.28%)

05:59
04/28/17
04/28
05:59
04/28/17
05:59
Earnings
Portland General Electric reports Q1 EPS 82c, consensus 82c »

Reports Q1 revenue $530M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

GOOG

Alphabet

$874.25

2.52 (0.29%)

, GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

05:58
04/28/17
04/28
05:58
04/28/17
05:58
Recommendations
Alphabet, Alphabet Class A analyst commentary  »

Alphabet price target…

GOOG

Alphabet

$874.25

2.52 (0.29%)

GOOGL

Alphabet Class A

$891.44

2.3 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 16

    May

  • 22

    May

PCLN

Priceline

$1,835.87

31.75 (1.76%)

05:55
04/28/17
04/28
05:55
04/28/17
05:55
Recommendations
Priceline analyst commentary  »

Priceline price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 09

    May

WY

Weyerhaeuser

$34.67

0.41 (1.20%)

05:54
04/28/17
04/28
05:54
04/28/17
05:54
Hot Stocks
Weyerhaeuser sees Q2 Timberlands earnings, adj. EBITDA comparable to last year »

Weyerhaeuser anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

WY

Weyerhaeuser

$34.67

0.41 (1.20%)

05:51
04/28/17
04/28
05:51
04/28/17
05:51
Earnings
Weyerhaeuser reports Q1 EPS 21c, consensus 18c »

Reports Q1 revenue $1.7B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

CYAD

Celyad

05:47
04/28/17
04/28
05:47
04/28/17
05:47
Hot Stocks
Celyad initiates second dose escalation in THINK trial in first U.S. patient »

Celyad announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

GWB

Great Western

$43.11

-1.73 (-3.86%)

05:44
04/28/17
04/28
05:44
04/28/17
05:44
Downgrade
Great Western rating change  »

Great Western downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$46.91

0.49 (1.06%)

05:43
04/28/17
04/28
05:43
04/28/17
05:43
Earnings
Sanofi sees FY17 business EPS stable to down 3% at CER »

Sanofi expects 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

SNY

Sanofi

$46.91

0.49 (1.06%)

05:43
04/28/17
04/28
05:43
04/28/17
05:43
Earnings
Sanofi reports Q1 business EPS EUR 1.42 vs. EUR 1.34 last year »

Reports Q1 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

REGN

Regeneron

$366.62

-4.77 (-1.28%)

, SNY

Sanofi

$46.91

0.49 (1.06%)

05:38
04/28/17
04/28
05:38
04/28/17
05:38
Hot Stocks
Regeneron, Sanofi announce Kevzara BLA resubmission accepted by FDA »

Regeneron Pharmaceuticals…

REGN

Regeneron

$366.62

-4.77 (-1.28%)

SNY

Sanofi

$46.91

0.49 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 07

    May

BLDP

Ballard Power

$3.14

0.14 (4.67%)

05:36
04/28/17
04/28
05:36
04/28/17
05:36
Hot Stocks
Ballard Power signs further follow-on agreement with global auto OEM »

Ballard Power Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

CHKP

Check Point

$104.39

0.17 (0.16%)

05:36
04/28/17
04/28
05:36
04/28/17
05:36
Upgrade
Check Point rating change  »

Check Point upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 12

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.